Distinguishing viable tumor from treatment-altered fibrosis during cancer surgery remains a major challenge in contemporary oncology. Neoadjuvant chemotherapy, radiotherapy, immunotherapy, and targeted treatment can produce dense fibrosis, necrosis, inflammation, and tissue remodeling that resemble persistent malignancy on inspection, palpation, and conventional imaging. Fluorescence-lifetime imaging offers a complementary optical strategy by measuring the time-dependent decay of fluorophore emission rather than relying solely on fluorescence intensity. Because tissue composition, molecular binding, pH, oxygenation, and extracellular matrix organization influence fluorescence lifetime, this approach may identify biochemical differences between residual cancer and benign post-treatment change. Early laboratory, ex vivo, and intraoperative studies suggest that fluorescence-lifetime measurements can improve tissue characterization, guide surgical margins, and support real-time decision-making. However, clinical translation requires standardized instrumentation, validated diagnostic thresholds, assessment across tumor types and treatment regimens, and prospective comparison with histopathology and established imaging. This review summarizes the biological rationale, clinical applications, potential benefits, limitations, and future scope of fluorescence-lifetime imaging for distinguishing tumor tissue from treatment-altered fibrosis during cancer surgery.
Complete removal of malignant tissue while preserving uninvolved anatomy is a central objective of oncologic surgery. The task becomes particularly difficult after neoadjuvant treatment, when the operative field may contain a mixture of viable tumor, acellular fibrosis, treatment-related inflammation, edema, hemorrhage, and necrosis. These components can have similar color, firmness, and gross appearance. Conventional cross-sectional imaging also has limitations because residual enhancement, diffusion abnormalities, and architectural distortion may reflect either active malignancy or treatment response. In this setting, an intraoperative technique that provides rapid, objective, and biologically informative tissue assessment could improve surgical precision.
Fluorescence-lifetime imaging measures the interval between excitation of a fluorescent molecule and return to its ground state. Unlike fluorescence intensity, which is strongly affected by tissue thickness, illumination, probe concentration, and optical geometry, lifetime is comparatively less dependent on signal quantity. It can therefore provide information about the local molecular environment. Endogenous fluorophores, including reduced nicotinamide adenine dinucleotide, flavins, collagen, elastin, and porphyrin-related compounds, exhibit distinct lifetime behavior that changes with metabolism, protein binding, fibrosis, and tissue organization. Exogenous fluorescent agents may add tumor specificity when their distribution or intracellular binding differs between viable tumor and scar tissue.
The burden of this diagnostic problem is substantial because multimodal treatment is increasingly used for locally advanced and biologically aggressive cancers. Neoadjuvant therapy is established or expanding in breast, rectal, esophageal, gastric, pancreatic, bladder, ovarian, head and neck, and selected sarcoma treatment pathways. A pathological complete response may occur despite persistent radiographic or palpable abnormalities, whereas small islands of viable tumor can remain within extensive treatment-induced fibrosis. The clinical consequences of misclassification are considerable. Underestimation of residual disease may lead to positive margins, local recurrence, or inappropriate omission of additional treatment. Overestimation may result in unnecessarily extensive resection, organ loss, postoperative morbidity, and impaired quality of life.
Margin assessment remains especially challenging in anatomically complex regions such as the pancreas, pelvis, mediastinum, and head and neck. Frozen-section analysis can provide high-value information but is limited by sampling, processing time, tissue distortion, and the need for specialist pathology support. Fluorescence-lifetime imaging is not intended to replace histopathology; rather, its potential value lies in surveying a larger operative field and directing biopsies or additional resections toward regions most likely to contain viable tumor.
Treatment-altered fibrosis develops through persistent inflammatory signaling, fibroblast activation, extracellular matrix deposition, vascular remodeling, and replacement of damaged tumor and stromal cells with collagen-rich scar. Radiation can produce endothelial injury, hypoxia, chronic cytokine release, and progressive matrix cross-linking. Cytotoxic chemotherapy may induce cell death and tissue repair, while immune-based treatments can generate lymphocytic infiltration, edema, and necrosis. These processes create substantial spatial heterogeneity, meaning that a single lesion may contain viable tumor, scar, and necrotic compartments within millimeters of one another.
Viable malignant tissue generally demonstrates altered energy metabolism, increased cellularity, abnormal redox balance, angiogenesis, and heterogeneous oxygenation. These biological features influence endogenous fluorescence. The relative abundance and binding state of nicotinamide adenine dinucleotide and flavins can change with glycolytic activity and mitochondrial function. Collagen-rich fibrosis may produce a different lifetime signature because structural proteins have distinct fluorescence properties and molecular environments. Lifetime variation may also reflect changes in tissue acidity, protein interactions, intracellular viscosity, and oxygen-dependent quenching. Importantly, no single lifetime pattern is universally diagnostic. Tumor subtype, treatment exposure, inflammation, necrosis, and technical factors can alter the optical phenotype, requiring disease-specific validation.
Factors associated with difficult intraoperative discrimination include intensive neoadjuvant treatment, combined chemotherapy and radiotherapy, delayed surgery after radiation, infiltrative tumor growth, poorly defined baseline margins, desmoplastic tumor biology, and anatomic proximity to critical structures. Recurrent tumors may be particularly challenging because prior surgery and radiation produce dense adhesions and altered vascularity. Patient-related factors such as diabetes, smoking, vascular disease, and impaired wound healing may further modify inflammation and fibrosis. The risk of residual disease also depends on tumor stage, treatment sensitivity, molecular subtype, and the presence of radiographic or biochemical evidence of incomplete response.
These factors reinforce the need for multimodal interpretation. A fluorescence-lifetime signal should not be treated as an isolated risk marker. It must be integrated with pretreatment imaging, treatment response assessment, operative findings, tumor anatomy, serum biomarkers where validated, and the clinical treatment plan.
Residual tumor and treatment-altered fibrosis may both present as a firm, irregular, or poorly demarcated region. In the abdomen, desmoplastic reaction can tether bowel, vessels, or bile ducts and mimic direct invasion. In breast and soft-tissue surgery, post-treatment changes may obscure the original tumor bed. In rectal cancer, fibrosis can cause wall thickening and reduced tissue compliance, while microscopic residual disease may be distributed unevenly around the treated lesion. Such overlap makes visual and tactile assessment unreliable, particularly when the surgeon must balance oncologic clearance against preservation of nerves, vessels, sphincters, or organ function.
Current diagnostic assessment combines magnetic resonance imaging, computed tomography, positron emission tomography when appropriate, ultrasound, endoscopy, physical examination, and pathology. Each modality provides different information, but none consistently identifies every microscopic focus of viable disease after treatment. Positron emission tomography may be confounded by inflammation, whereas diffusion restriction and contrast enhancement on magnetic resonance imaging can persist in fibrosis. Intraoperative ultrasound can improve localization but generally does not provide definitive biological classification.
Fluorescence-lifetime imaging uses a pulsed or modulated light source and time-resolved detection to calculate the decay profile of emitted photons. Systems may be implemented through a handheld probe, microscope, endoscope, laparoscope, or wide-field camera. Data can be displayed as lifetime maps, tissue classifications, or probability estimates. Research workflows commonly compare measurements from tumor, fibrosis, normal tissue, and necrosis against histopathological reference standards. Key diagnostic metrics include sensitivity, specificity, positive predictive value, negative predictive value, area under the receiver operating characteristic curve, spatial resolution, acquisition time, and reproducibility between operators and institutions.
For clinical use, calibration is essential. Measurements can be influenced by probe-tissue distance, surface angle, ambient light, blood contamination, motion, optical scattering, and variations in tissue hydration. Algorithms should therefore be trained on representative, prospectively collected datasets and externally validated. Reporting should distinguish per-pixel, per-region, and per-patient performance, because apparently strong pixel-level results may not translate into reliable surgical decisions.
The primary management principle remains treatment according to multidisciplinary oncologic assessment and established surgical standards. Fluorescence-lifetime imaging may support, but should not independently determine, resection margins or omission of surgery. During an operation, imaging could be used to survey the tumor bed, identify suspicious regions, guide targeted biopsies, and prompt additional assessment of a margin before closure. Its greatest practical value may be reducing uncertainty in areas where extended resection would cause major morbidity or where conventional inspection is ambiguous.
Integration with fluorescence-guided surgery using tumor-targeted probes is a promising strategy. Intensity-based agents may provide molecular localization, while lifetime information could improve discrimination of specific probe environments or separate true target accumulation from nonspecific background. A combined platform could therefore provide both anatomical localization and biochemical characterization. Nevertheless, safety, regulatory approval, probe pharmacology, timing of administration, renal and hepatic clearance, and potential immunogenicity must be addressed for every exogenous agent.
Recent technological development has focused on faster time-resolved detectors, compact fiber-optic probes, multispectral lifetime acquisition, and machine-learning classifiers. Deep learning may identify subtle combinations of lifetime components that are difficult to interpret using a single average value. Hybrid systems combining lifetime, spectral, Raman, optical coherence, or hyperspectral measurements may improve robustness by integrating complementary biochemical and structural information. Three-dimensional mapping and robotic or laparoscopic compatibility could permit assessment of deep or minimally accessible operative surfaces.
Emerging research is also examining lifetime changes during treatment, rather than only at surgery. Serial measurements may help characterize response kinetics, identify resistant subregions, and support adaptive treatment planning. However, algorithmic performance can decline when applied to a different hospital, device, tumor type, or treatment protocol. Prospective multicenter studies, locked analytical pipelines, and transparent reporting are required to establish generalizability. Clinical trials should evaluate not only diagnostic accuracy but also margin positivity, reoperation rates, organ preservation, complications, recurrence, operative time, and patient-reported outcomes.
Current major surgical and oncology guidelines support histopathological examination as the definitive standard for confirming residual malignancy and margin status. They also emphasize multidisciplinary planning, appropriate pretreatment staging, evidence-based neoadjuvant therapy, and careful correlation of imaging with clinical and operative findings. Fluorescence-lifetime imaging is best regarded as an investigational or adjunctive technology until adequate prospective evidence demonstrates that its use improves clinically meaningful outcomes.
For responsible implementation, institutions should establish standardized acquisition protocols, quality-control procedures, operator training, data governance, and predefined criteria for acting on an imaging result. Any discordance between lifetime imaging and surgical or pathological judgment should be documented and analyzed. Regulatory oversight should address device performance, software updates, cybersecurity, and the risk of automation bias. Use within a clinical trial or prospective registry is appropriate when the technology is not yet validated for routine care.
The clinical relevance of fluorescence-lifetime imaging lies in its potential to convert a visually ambiguous treatment bed into a biologically mapped surgical field. More accurate identification of residual tumor could support complete resection while limiting unnecessary removal of fibrotic but disease-free tissue. This may be particularly valuable in organ-preserving procedures, reoperations, and cancers in which a few millimeters determine whether critical anatomy can be retained. The technology could also improve pathology efficiency by directing sampling toward diagnostically informative areas.
Important risks include false-negative readings caused by low tumor cellularity, sampling limitations, necrotic masking, or device insensitivity, as well as false-positive readings from inflammation, infection, dense collagen, or treatment-related metabolic changes. Incorrect interpretation could either compromise oncologic control or increase surgical morbidity. These risks make transparent uncertainty estimates and direct correlation with pathology essential.
Experts in optical imaging and surgical oncology generally emphasize that lifetime should be interpreted as a multidimensional biological signal rather than a universal cancer fingerprint. The most credible clinical pathway is incremental: first establish reproducible separation of well-defined tissue classes, then demonstrate feasibility in the operating room, and finally test whether imaging changes decisions and improves outcomes. Surgeons, pathologists, physicists, engineers, radiologists, and biostatisticians should participate in study design. Histological registration, blinded validation, and inclusion of treated benign tissue are particularly important because many early studies risk overestimating performance when controls are biologically dissimilar to the real operative setting.
Future research should prioritize prospective, multicenter investigations across tumor types and treatment regimens, with standardized definitions of fibrosis, residual tumor, and clinically relevant margins. Studies should evaluate whether lifetime imaging adds value beyond magnetic resonance imaging, positron emission tomography, intraoperative ultrasound, frozen section, and targeted fluorescence. Better models may combine lifetime distributions with patient history, radiomics, pathology, and molecular subtype while preserving interpretable outputs. Real-time integration with navigation platforms could eventually provide decision support without interrupting surgical workflow.
Before widespread adoption, investigators must define clinically meaningful thresholds, assess cost-effectiveness, measure learning curves, and determine how results should be communicated when confidence is low. The most important endpoint is not merely classification accuracy but improved patient care, including fewer positive margins, fewer unnecessary radical resections, lower recurrence, and acceptable operative safety.
Fluorescence-lifetime imaging is a promising adjunct for differentiating viable tumor from treatment-altered fibrosis during cancer surgery. Its mechanistic foundation rests on treatment- and disease-related changes in endogenous fluorophores, metabolism, extracellular matrix, and molecular microenvironment. Early evidence supports feasibility and biological discrimination, but substantial technical and clinical validation remains necessary. At present, the technology should complement rather than replace pathology, conventional imaging, and multidisciplinary judgment. With rigorous standardization, prospective outcome studies, and careful integration into surgical workflows, fluorescence-lifetime imaging may improve margin assessment, support organ preservation, and advance precision surgery for patients whose anatomy has been transformed by cancer treatment.
1.
Big Comeback for Myeloma Drug; DIY Cancer Therapy; Gut Clues to Bladder Cancer
2.
Pressing the Sleep button could have a positive impact on cognition.
3.
Simpler Screening Criteria Could Catch More Lung Cancers
4.
An understudied type of breast cancer poses a lurking threat
5.
By acquiring T3 Pharma, a leader in bacterial cancer treatment, Boehringer Ingelheim broadens its offering in immunooncology.
1.
Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment
2.
Exploring the Unseen: Carcinoid Syndrome and its Impact on Quality of Life
3.
Revolutionizing Cancer Treatment: The Promise of Bevacizumab Injections
4.
All You Need To Know About Cancer Antigen 27-29: Causes, Symptoms & Treatment
5.
Multiple Primary Lung Cancer: Multidisciplinary Advances in Diagnosis and Care
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Future of Hematology
2.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
3.
The Role of Platelets in Normal Blood Clotting
4.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
5.
Understanding Common Causes of Abnormal Blood Counts
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation